<DOC>
	<DOCNO>NCT00005799</DOCNO>
	<brief_summary>This clinical trial study fludarabine phosphate , low-dose total body irradiation , donor stem cell transplant treat patient hematologic malignancy kidney cancer . Giving chemotherapy drug , fludarabine phosphate , total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine transplant cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate , Low-Dose Total Body Irradiation , Donor Stem Cell Transplant Treating Patients With Hematologic Malignancies Kidney Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether stable allogeneic engraftment unrelated hematopoietic stem cell donor safely establish use non-myeloablative conditioning regimen patient hematologic malignancy renal cell carcinoma . SECONDARY OBJECTIVES : I . To evaluate whether donor lymphocyte infusion ( DLI ) safely used patient mixed full donor chimerism eliminate persistent progressive disease . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 . Patients also undergo low-dose total-body irradiation ( TBI ) day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell ( PBSC ) bone marrow transplantation day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 100 taper day 177 mycophenolate mofetil PO BID day 0-40 taper day 96 . Patients mixed chimerism , persistent progressive disease , evidence graft-versus-host disease immunosuppression least 2 week undergo DLI 30 minute . DLI may repeat every 65 day 3 dos . After completion study treatment , patient follow-up periodically 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age &gt; 50 year hematologic malignancy treatable allogeneic hematopoietic stem cell transplant ( HSCT ) patient B cell malignancy except may cure autologous stem cell transplantation ( SCT ) Age = &lt; 50 year age hematologic diseases treatable allogeneic HSCT preexist medical condition prior therapy consider high risk regimen relate toxicity associate conventional transplant patient refuse conventional SCT ; transplant must approve inclusion criterion participate institution 's patient review committee Patient Care Conference ( PCC Fred Hutchinson Cancer Research Center [ FHCRC ] ) principal investigator Patients metastatic renal cell carcinoma histologic subtypes clear cell , papillary medullary may accept regardless age The following disease permit although diagnosis consider approve PCC participate institution 's patient review committee principal investigator NonHodgkin lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) , Hodgkin lymphoma ( HL ) must receive failed frontline therapy Multiple myeloma must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HSCT permit Acute myeloid leukemia ( AML ) /acute lymphoblastic leukemia ( ALL ) must complete remission receive cytotoxic chemotherapy stage transplant ; patient molecular early relapse accept provide donor available ; patient persistent refractory disease consider case case basis transplant must approve institution 's patient review committee Chronic myelogenous leukemia ( CML ) patient accept chronic phase accelerate phase ; patient receive prior autograft high dose therapy undergone intensive chemotherapy either peripheral blood stem cell ( PBSC ) mobilization treatment advance CML may enrol provide complete remission ( CR ) , chronic phase ( CP ) accelerate phase ( AP ) Myelodysplastic syndrome ( MDS ) patient MDS eligible protocol ; however , patient MDS frank AML ( &gt; 30 % blast bone marrow aspirate morphology flow cytometry ) require induction chemotherapy obtain complete remission ( marrow blast &lt; 5 % ) remain complete remission time transplant Renal cell carcinoma must evidence disease amenable surgical cure metastatic disease radiological histological criterion DONOR : Human leukocyte antigen ( HLA ) match unrelated donor ; donor match HLA A , B , C , developmentally regulate ribonucleic acid ( RNA ) bind protein 1 ( DRB ) 1 class II , DQ beta 1 ( DQB ) 1 ; HLA A B locus match least level resolution ; HLA C , DRB1 , DQB1 type high level resolution available time donor selection ; donor must consent either bone marrow harvest PBSC mobilization filgrastim ( GCSF ) arrange National Marrow Donor Program ( NMDP ) donor center Patients rapidly progressive intermediate high grade NHL Renal cell carcinoma patient expect survival less 6 month Bulky disease result severely limited performance status ( &lt; 70 % ) Any vertebral instability Any active central nervous system ( CNS ) involvement disease Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant Patients nonhematological tumor Cardiac ejection fraction &lt; 30 % Diffusion capacity lung carbon monoxide ( DLCO ) &lt; 30 % and/or receive supplementary continuous oxygen Significant elevation bilirubin transaminase discuss participate institution ' patient review committee case case basis ; evidence synthetic dysfunction severe cirrhosis result patient exclusion Karnofsky score &lt; 50 ( except renal cell carcinoma [ RCC ] ) Patients poorly control hypertension multiple antihypertensives Human immunodeficiency virus ( HIV ) positive patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>